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   The pathogenesis of Alzheimer’s disease (AD) is characterized by cerebral deposits of amyloid 
ß-peptides (Aß) and neurofibrillary tangles which are surrounded by inflammatory cells.  Long-term 
uses of non-steroidal anti-inflammatory drugs (NSAIDs) reduce the risk of developing AD and delay 
the onset of the disease.  In the present study, we used fluorescence spectroscopy with thioflavin T and 
electron microscopy to examine the effects of NSAIDs such as ibuprofen, aspirin, meclofenamic acid 
sodium salt, diclofenac sodium salt, ketoprofen, flurbiprofen, naproxen, sulindac sulfide and 
indomethacin on the formation, extension, and destabilization of ß-amyloid fibrils (fAß) at pH 7.5 at 
37˚C in vitro.  All examined NSAIDs dose-dependently inhibited formation of fAß from fresh 
Aß(1-40) and Aß(1-42), as well as their extension.  Moreover, these NSAIDs dose-dependently 
destabilized preformed fAßs.  The overall activity of the molecules examined was in the following 
order: ibuprofen ≈ sulindac sulfide ≥ meclofenamic acid sodium salt > aspirin ≈ ketoprofen ≥ 
flurbiprofen ≈ diclofenac sodium salt > naproxen ≈ indomethacin.  Although the mechanisms by 
which these NSAIDs inhibit fAß formation from Aß, and destabilize preformed fAß in vitro are still 
unclear, NSAIDs may be promising for the prevention and treatment of AD.   
 
Keywords: Alzheimer’s disease; ß-amyloid fibrils; electron microscopy; non-steroidal 
anti-inflammatory drugs; thioflavin T. 
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1. Introduction  
 
   In the pathogenesis of Alzheimer’s disease (AD), the abundance of intraneural neurofibrillary 
tangles and the extracellular deposition of the amyloid ß-peptide (Aß) as amyloid plaques and vascular 
amyloid are seminal events (Selkoe, 2001).  The aggregation of Aß and ß-sheet formation are 
considered to be critical events that render these peptides neurotoxic (Pike et al., 1995).  The presence 
of chronic neuroinflammation also contributes to the protracted degenerative course of AD (McGeer 
and McGeer, 1995), and it is also common to other neurodegenerative disorders, such as Parkinson’s 
disease and Creutzfelt-Jacob disease (Eikelenboom et al., 2002; Gao et al., 2003).  A chronic 
inflammatory response characterized by activated microglia, reactive astrocytes, complement factors, 
and increased inflammatory cytokine expression associated with Aß deposits has been described in the 
brain of AD patients (Rogers et al., 1996).  A number of epidemiological studies have demonstrated a 
reduced risk for AD in population with long-term use of non-steroidal anti-inflammatory drugs 
(NSAIDs) (McGeer et al., 1996; in t’Veld et al., 1998; Akiyama et al., 2000; in t’Veld et al., 2001).    
   These epidemiological findings have been supported by experimental studies.  First, chronic 
ibuprofen (Ibu) treatment significantly diminished amyloid deposition (Lim et al., 2000), and improved 
behavioral impairment in the APPsw transgenic mouse (Tg2576) (Lim et al., 2001).  Second, a subset 
of NSAIDs such as Ibu, sulindac sulfide (SSide), indomethacin (Ind) (Weggen et al., 2001) and 
flurbiprofen (Flu) (Eriksen et al., 2003) selectively decreased the secretion of Aß(1-42) from cultured 
cells independently of cyclooxygenase (COX) activity and lowered the amount of soluble Aß(1-42) in 
the brains of Tg2576 mouse.  Third, SSide and enantiomers of Flu have been reported to target 
γ-secretase and preferentially reduce Aß(1-42) generation (Takahashi et al., 2003; Eriksen et al., 2003).  
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These data suggest that some of the NSAIDs may affect the pathogenetic process of AD directly.  
However, except the preliminary study where Thomas et al. (2001) used the non-physiological short 
peptide Aß(25-35), the effects of NSAIDs on the formation and destabilization of Alzheimer’s 
ß-amyloid fibrils (fAß) in vitro have not been studied in detail.   
   Using a nucleation-dependent polymerization model explaining the mechanism of fAß formation in 
vitro (Jarrnet and Lansbury, 1993; Naiki and Gejyo, 1999), we previously found that 
nordihydroguaiaretic acid (NDGA) and rifampicin (Rif) inhibit fAß formation from Aß and fAß 
extention dose-dependently (Naiki et al., 1998).  Moreover, we reported that they also destabilize 
fAß(1-40) and fAß(1-42) in a concentration-dependent manner within a few hours at pH 7.5 at 37˚C, 
based on fluorescence spectroscopic analysis with thioflavin T (ThT) and electron microscopic studies 
(Ono et al., 2002b).   
   Here, we examined the effects of the major NSAIDs on the formation, extension, and 
destabilization of fAß(1-40) and fAß(1-42) at pH 7.5 and 37˚C in vitro, using fluorescence spectroscopy 




2.1.  Preparation of Aß and fAß solutions 
 
   Aß(1-40) (trifluoroacetate salt, lot number 540111 and 530108, Peptide Institute Inc., Osaka, Japan) 
and Aß(1-42) (trifluoroacetate salt, lot number 540127 and 530914, Peptide Institute Inc., Osaka, Japan) 
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were dissolved by brief vortexing in 0.02% ammonia solution at a concentration of 500 µM (2.2 
mg/mL) and 250 µM, respectively, in a 4˚C room and stored at -80˚C before assaying (fresh Aß(1-40) 
and Aß(1-42) solutions).  fAß(1-40) and fAß(1-42) were formed from the fresh Aß(1-40) and 
Aß(1-42) solutions, respectively, sonicated, and stored at 4˚C as described elsewhere (Hasegawa et al., 
1999).  
   Fresh, non-aggregated fAß(1-40) and fAß(1-42) were obtained by extending sonicated fAß(1-40) or 
fAß(1-42) with fresh Aß(1-40) or Aß(1-42) solutions, respectively, just before the destabilization 
reaction (Ono et al., 2002a; 2002b) .  The reaction mixture was 600 µL and contained 10 µg/mL (2.3 
µM) fAß(1-40) or fAß(1-42), 50 µM Aß(1-40) or Aß(1-42), 50 mM phosphate buffer, pH 7.5, and 100 
mM NaCl.  After incubation at 37˚C for 3-6 h under non-agitated conditions, the extension reaction 
proceed to equilibrium as measured by the fluorescence of ThT.  In the following experiment, the 
concentration of fAß(1-40) and fAß(1-42) in the final reaction mixture was regarded as 50 µM.   
  
2.2.  Fluorescence spectroscopy, electron microscopy, and polarized light microscopy.  
 
   A fluorescence spectroscopic study was performed as described by Naiki and Nakakuki (1996) on a 
Hitachi F-2500 fluorescence spectrophotometer (Tokyo, Japan).  Optimum fluorescence measurement 
of fAß(1-40) and fAß(1-42) were obtained at the excitation and emission wavelengths of 445 and 490 
nm, respectively, with the reaction mixture containing 5 µM ThT (Wako Pure Chemical Industries Ltd, 
Osaka, Japan) and 50 mM of glycine-NaOH buffer, pH 8.5.  An electron microscopic study and 
polarized light microscopic study of the reaction mixtures were performed as described elsewhere 
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(Hasegawa et al., 1999).   
 
2.3.  Polymerization assay 
 
   Polymerization of Aß with or without fAß added as seeds was assayed as described elsewhere 
(Naiki et al., 1998).  The reaction mixture contained 50 µΜ Aß(1-40), or 25 or 50 µΜ Aß(1-42), 0 or 
10 µg/mL fAß(1-40) or fAß(1-42), 0, 0.01, 0.1, 1, 10, or 50 µΜ NSAIDs (Ibu, aspirin (Asp), 
meclofenamic acid sodium salt (Mec), diclofenac sodium salt (Dic), ketoprofen (Ket), Flu, naproxen 
(Nap), SSide, Ind), NDGA, Rif, or nicotine (Sigma Chemical Co., St. Louis, MO, USA), 1% dimethyl 
sulfoxide (DMSO) (Nacakai Tesque, Inc., Kyoto, Japan), 50 mΜ phosphate buffer, pH 7.5, and 100 
mΜ NaCl.  NSAIDs dissolved in DMSO at concentrations of 1, 10, 100 µM, 1 mΜ and 5 mΜ, were 
added to the reaction mixture to make the final concentration 0.01, 0.1, 1, 10 µΜ and 50 µΜ, 
respectively.   
   Aliquots (30 µL) of the mixture were put into oil-free PCR tubes (size: 0.5 mL, code number: 9046; 
Takara Shuzo Co. Ltd, Otsu, Japan).  The reaction tubes were then put into a DNA thermal cycler 
(PJ480; Perkin Elmer Cetus, Emeryville, CA, USA).  The plate temperature was elevated at maximal 
speed, starting at 4˚C, to 37˚C.  Incubation times ranged between 0 and 8 days (as indicated in each 
figure), and the reaction was stopped by placing the tubes on ice.  The reaction tubes were not agitated 
during the reaction.  From each reaction tube, triplicate 5 µL aliquots were removed, then subjected to 
fluorescence spectroscopy and the mean of each triplicate determined.  In the ThT solution, the 
concentration of NSAIDs examined in this study was diluted up to 1/200 of that in the reaction mixture.  
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We confirmed that these compounds did not quench ThT fluorescence at the diluted concentration (data 
not shown).   
 
2.4.  Destabilization assay 
 
   Destabilization of fAß was assayed as described elsewhere (Ono et al., 2002b).  Briefly, the 
reaction mixture contained 25 µM fresh fAß(1-40) or fAß(1-42), 0, 0.01, 0.1, 1, 10 or 50 µΜ NSAIDs, 
NDGA, Rif, or nicotine, 1% DMSO, 50 mΜ phosphate buffer, pH 7.5, 100 mΜ NaCl, and 1% (wt/vol) 
polyvinyl alcohol (Wako Pure Chemical Industries Ltd) to avoid the aggregation of fAß and the 
adsorption of fAß onto the inner wall of the tube during the reaction.   
   After being mixed by pipetting, triplicate 5 µL aliquots were subjected to fluorescence spectroscopy 
and 30 µL aliquots were put into oil-free PCR tubes (Takara Shuzo Co. Ltd, Otsu, Japan).  The 
reaction tubes were then transferred into a DNA thermal cycler (Perkin Elmer Cetus, Emeryville, 
California).  Starting at 4˚C, the plate temperature was elevated at maximal speed to 37˚C.  
Incubation times ranged from 0 to 24 h (as indicated in each figure), and the reaction was stopped by 
placing the tubes on ice.  The reaction tubes were not agitated during the reaction.  From each 
reaction tube, 5 µL aliquots in triplicate were subjected to fluorescence spectroscopy and the mean of 
the three measurements was determined.  ThT fluorescence did not change significantly when fAß 
were incubated with 0-50 µM of NSAIDs at either 4˚C or 37˚C for 1 min, then subjected to ThT assay, 
indicating that these compounds did not compete with ThT for fAß (data not shown).  
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2.5.  Other analytical procedures 
 
   Protein concentrations of Aßs and fAßs in the reaction mixtures were determined by the method of 
Bradford (1976) with a protein assay kit (Bio-Rad Laboratories, Inc., Hercules, CA).  The Aß(1-40) 
solution quantified by amino acid analysis was used as the standard.  The linear least squares fit and 
one-way analysis of variance, post-hoc test by Scheffe were used for statistical analysis. 
 
3. Results  
 
3.1.  Effect of NSAIDs on the kinetics of fAß polymerization 
 
   As shown in Fig. 1A-D, the fluorescence of ThT followed a characteristic sigmoidal curve when 
fresh Aß(1-40) or Aß(1-42) was incubated at 37˚C.  This curve is consistent with a 
nucleation-dependent polymerization model (Jarrett and Lansbury, 1993; Naiki and Gejyo, 1999).  
Fresh fAß(1-40) assumed a non-branched, helical filament structure of approximately 10 nm width and 
exhibited a helical periodicity of approximately 220 nm.  In the fresh fAß(1-42) solution, two types of 
filaments of approximately 8 and 12 nm width were observed.  Although the Aß batches used here 
were different from those in our previous experiments, these morphologies of fAßs were similar to 
those reported previously (Naiki and Nakakuki, 1996; Naiki et al., 1998).  Both fAß(1-40) and 
fAß(1-42) stained with Congo red showed typical orange-green birefringence under polarized light.  
The final equilibrium level of Aß(1-40) or Aß(1-42) was lowered dose-dependently by incubation with 
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10 and 50 µM Ibu, Ket or Nap (Fig. 1A-D).  Other NSAIDs (Asp, Mec, Dic, Flu, SSide and Ind) also 
significantly inhibited the polymerization of Aß(1-40) and Aß(1-42) (Fig. 6A, B).   
   As shown in Fig. 2A-D, the fluorescence increased hyperbolically without a lag phase and 
proceeded to equilibrium much more rapidly by incubation of fresh Aß(1-40) or Aß(1-42) with 
fAß(1-40) or fAß(1-42), respectively, at 37˚C, than that without seeds (compare Fig. 1A, B, and 2A, B).  
This curve is consistent with a first-order kinetic model (Naiki and Nakakuki, 1996).  The final 
equilibrium level was dose-dependently decreased by incubation of Aß(1-40) or Aß(1-42) with 
fAß(1-40) or Aß(1-42), respectively, with 10 or 50 µM Ibu, Ket or Nap (Fig. 2A-D).  Other NSAIDs 
(Asp, Mec, Dic, Flu, SSide and Ind) also significantly inhibited the extension of fAß(1-40) and 
fAß(1-42) (data not shown).   
   As shown in Fig. 2E, at a constant fAß(1-40) concentration, a good linearity was observed between 
the Aß(1-40) concentration and the initial rate of fAß(1-40) extension both in the presence and absence 
of Ibu.  This linearity is again consistent with a first-order kinetic model and indicates that at each 
Aß(1-40) concentration, the net rate of fAß(1-40) extension is the sum of the rates of polymerization 
and depolymerization (Naiki and Nakakuki, 1996; Hasegawa et al., 2002).  In the presence of 10 µΜ 
Ibu, the slope of the straight line decreased to about 36%.   
   As shown in Fig. 3B, clear fibril extension was observed by electron microscopy when fresh 
Aß(1-40) was incubated with fAß(1-40) at 37˚C.  However, 50 µM Ibu completely inhibited the 
extension of sonicated fAß(1-40) (Fig. 3A, C).  Ibu inhibited the extension of fAß(1-42) and other 
NSAIDs (Asp, Mec, Dic, Ket, Flu, Nap, SSide and Ind) also inhibited the extension of fAß(1-40) and 
fAß(1-42) (data not shown).   




3.2.  Effect of NSAIDs on the kinetics of fAß destabilization 
 
   As shown in Fig. 4A-D, the fluorescence of ThT was almost unchanged during the incubation of 
fresh fAß(1-40) or fAß(1-42) at 37˚C without additional molecules.  On the other hand, the ThT 
fluorescence decreased immediately after addition of NSAIDs to the reaction mixture.  As shown in 
Fig. 4A-D, the ThT fluorescence of fAß(1-40) and fAß(1-42) decreased immediately after addition of 
Ibu, Ket, Nap, in a concentration-dependent manner.  Other NSAIDs (Asp, Mec, Dic, Flu, SSide and 
Ind) also significantly destabilized fAß(1-40) and fAß(1-42) (Fig. 6C, D).   
   After incubation of 25 µM fresh fAß(1-40) with 50 µM Ibu for 1 h, many short, sheared fibrils were 
observed (Fig. 5B).  At 6 h, the number of fibrils was markedly decreased, and small amorphous 
aggregates were occasionally observed (Fig. 5C).  Ibu destabilized fresh fAß(1-42) and other NSAIDs 
(Asp, Mec, Dic, Ket, Flu, Nap, SSide and Ind) also destabilized preformed fAß(1-40) and fAß(1-42) 
(data not shown).   
   As shown in Fig. 6, statistical analysis revealed a significant difference in the potency of 50 µM 
NSAIDs for the anti-polymerization effect (A, B) and for the fibril destabilizing effect (C, D).  In both 
the cases of fAß(1-40) and fAß(1-42), the potency of NSAIDs for the anti-polymerization effect was 
similar to that for the fibril-destabilizing effect.  Additionally, similar anti-polymerization and 
fibril-destabilizing effects were observed for both fAßs.  The overall activity of the molecules 
examined was in the order of: Ibu ≈ SSide ≥ Mec > Asp ≈ Ket ≥ Flu ≈ Dic > Nap ≈ Ind.  We finally 
compared the anti-amyloidogenic and fibril-destabilizing activity of SSide and Ibu with that of NDGA, 
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Rif, and nicotine (Fig. 7).  Although NDGA exhibited the potent anti-amyloidogenic and 
fibril-destabilizing activity dose-dependently, the activity of nicotine was weak or negligible.  Rif, 
SSide and Ibu exhibited similar dose-dependent activity. 
   After incubation with 50 µM Ibu for 4 h, fAß(1-40) and fAß(1-42) were stained with Congo red 
much more weakly than fresh fAß(1-40) and fAß(1-42), but they all showed orange-green 
birefringence under polarized light.  This means that a significant amount of intact fAß(1-40) and 
fAß(1-42) still remains in the mixture after the reaction, as shown in Fig. 5C.  No proteins were 
detected by the Bradford assay in the supernatant after centrifugation at 4˚C for 2 h at 1.6 x 104 g.  This 
implies that although Ibu could destabilize fAß(1-40) and fAß(1-42) to visible aggregates (Fig. 5C), 
they could not depolymerize fAß(1-40) and fAß(1-42) to monomers or oligomers of Aß(1-40) and 
Aß(1-42).  When fresh 50 µM Aß(1-40) or Aß(1-42) was incubated with 10 µg/mL of the pellet at 
37˚C, no increase in the fluorescence was observed for 6 h.  This implies that destabilized fAß(1-40) 




   In this study, we demonstrated that various NSAIDs dose-dependently inhibited formation of fAß 
from fresh Aß(1-40) and Aß(1-42), as well as their extension in vitro.  Moreover, these NSAIDs 
dose-dependently destabilized preformed fAßs. 
   Thomas et al. (2001) suggested that the anti-aggregation effect of NSAIDs may be due to their 
interaction with epitope 3-6 and/or 25-35 in Aß, which are considered crucial to Aß aggregation and 
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neurotoxicity.  As shown in Fig. 2E, the extension of fAß(1-40) followed a first-order kinetic model 
even in the presence of Ibu.  The net rate of fAß(1-40) extension is the sum of the rates of 
polymerization and depolymerization (Naiki and Nakakuki, 1996; Hasegawa et al., 2002).  Thus, one 
possible explanation for the finding in Fig. 2E may be that Ibu bound to the ends of extending 
fAß(1-40) and increased the rate of depolymerization by destabilizing the conformation of Aß(1-40) 
which has just been incorporated into the fibril ends.  Alternatively, Ibu would bind to Aß(1-40) and 
consequently decrease the rate of polymerization.  Tomiyama et al. (1996) suggested that Rif binds to 
Aß by hydrophobic interactions between its lipophilic ansa chain and the hydrophobic region of Aß, 
thus blocking associations between Aß molecules leading to fAß formation.  The anti-amyloidogenic 
and fibril-destabilizing activity of tetracycline (Tc), small-molecule anionic sulphonates or sulphates, 
melatonin, ß-sheet breaker peptides (iAß5) and nicotine may also be related to the propensity to bind to 
the specific sites of Aß (Kisilevsky et al. 1995; Soto et al. 1996; Pappolla et al. 1998; Forloni et al. 2001; 
Zeng et al. 2001).  Thus, it may be reasonable to consider that NSAIDs could exhibit their 
anti-amyloidogenic and fibril-destabilizing effects by directly binding to Aßs and/or fAßs. 
   Taking into consideration the findings we obtained previously by systematic in vitro studies, we 
judged the overall activity of the anti-amyloidogenic molecules to be in the order of: tannic acid >> 
NDGA = wine-related polyphenols (myricetin, morin, quercetin) >> Rif = Tc > poly(vinylsulfonic acid, 
sodium salt) = 1,3-propanedisulfonic acid, disodium salt > iAß5 > nicotine (Ono et al., 2002a; 2002b; 
2003; 2004a).  In this study, we observed that the activity of SSide and Ibu is similar to that of Rif (Fig. 
7).   
   Next, we considered the structure-activity relationships of NSAIDs and other anti-amyloidogenic 
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compounds.  The antioxidant compounds with hydroxyphenyl rings are suggested to bind specifically 
to Aß and/or fAß, inhibit fAß formation and/or destabilize preformed fAß (Ono et al., 2002b; 2003; 
2004a; 2004b; Li et al., 2004).  On the other hand, the NSAIDs examined in this study have no 
hydroxyphenyl rings (Fig. 8).  In general, these NSAIDs have an aromatic-based hydrophobic 
structure with some fused ring structures and methyl and/or carboxyl groups.  This structure might be 
quite suitable for specifically binding to free Aß and subsequently inhibiting the polymerization of Aß 
into fAß.  Alternatively, this structure might be suitable for a specific binding to fAß and subsequent 
destabilization of the ß-sheet rich conformation of Aß molecules in fAß.  Further studies, such as 
nuclear magnetic resonance experiments, are essential to reveal the exact structure-activity relationships 
for NSAIDs and other organic compounds that exhibit anti-amyloidogenic and fibril-destabilizing 
effects in vitro. 
   Clinically, Ibu has been used in the treatment of nerve-root compression pain.  Although their 
penetration into the cerebrospinal fluid (CSF) is 0.9-1.5 % of the plasma level, the CSF level of Ibu 
derivatives is the range 595-1241 ng h/ml in the patients taking oral doses of 800 mg Ibu (Bannwarth et 
al., 1995).  This corresponds to 2884-6016 µM h of Ibu, which were higher than the concentration 
used in the present study.  It is therefore conceivable that therapeutic doses of Ibu could provide a 
concentration sufficient to achieve the anti-amyloidogenic effects.  
   Recent epidemiological studies have revealed that long-term and/or short-term use of some 
NSAIDs may protect against AD (McGeer et al., 1996; in t’Veld et al., 1998; Akiyama et al., 2000; in 
t’Veld et al., 2001).  Our study and several reports on the effects of NSAIDs may well explain this 
correlation.  First, the major therapeutic effect of NSAIDs is believed to be due to their inhibition of 
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COX-1 and COX-2, leading to the suppression of prostaglandin synthesis and chronic 
neuroinflammation contributing to the protracted degenerative course of AD (McGeer and McGeer, 
1995; Akiyama et al., 2000).  Second, Weggen et al. (2001) recently suggested that a subset of 
NSAIDs including Ibu, SSide, Ind and R-Flu directly affect amyloid pathology in the brains of 
transgenic mouse by reducing the amount of soluble Aß(1-42) peptide levels independently of COX 
activity.  They also suggested that NSAIDs subtly alter γ-secreatase activity without significantly 
perturbing other amyloid precursor protein (APP) pathways or Notch cleavage.  Some NSAIDs were 
reported to lower Aß(1-42) levels selectively both in cultured cell and broken cell assays, suggesting 
that these compounds interact directly with the γ-secretase complex itself that generates Aß from human 
APP (Sagi et al., 2003; Eriksen et al., 2003).  In addition, a subset of NSAIDs can reduce Aß(1-42) 
through inhibition of Rho activity, which may regulate APP processing in a cell culture (Zhou et al., 
2003).  Finally, as shown in this paper, NSAIDs dose-dependently inhibit fAß formation from fresh 
Aß and their extension, as well as destabilize preformed fAß in vitro.  Thus, it may be reasonable to 
speculate that NSAIDs could prevent the development of AD, not only through suppressing chronic 
neuroinflammation and reducing the amount of soluble Aß(1-42) peptide levels, but also through 
directly inhibiting the deposition of fAß in the brain.  In relation to the latter scenario, it may be 
essential to evaluate the effect of NSAIDs on the Aß oligomer formation in a future study, because the 
Aß oligomer has been reported to be the most neurotoxic form of all the Aß aggregates (Gong et al., 
2003).  Yang et al. (2005) recently reported that curcumin prevented Aß42 oligomer formation and 
toxicity between 0.1 and 1.0 µM, which is consistent with our EC50 values of curcumin for the 
anti-amyloidogenic and fibril-destabilizing activity (Ono et al., 2004b).  Although the exact 
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mechanisms of anti-amyloidogenic and fibril-destabilizing activity of NSAIDs are unclear, the careful 
and safe use of them could contribute the prevention and therapy of AD and other kinds of human 
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Legends for figures 
 
Fig. 1.   Effects of Ibu (A, B), Ket (C), and Nap (D) on the kinetics of fAß(1-40) (A, C, D) and 
fAß(1-42) (B) formation from fresh Aß(1-40) and Aß(1-42), respectively.  The reaction mixtures 
containing 50 µM Aß(1-40) (A, C, D) or 25 µM Aß(1-42) (B), 50 mM phosphate buffer, pH 7.5, 100 
mM NaCl, and 0 (●), 10 (○), or 50 µM (□) of Ibu (A, B), Ket (C), or Nap (D), were incubated at 
37˚C for the indicated times.  Each point represents the mean of three 5 µL aliquots from the same 
sample.  Each figure is a representative pattern of 3 independent experiments.   
 
Fig. 2.   Effects of Ibu (A, B), Ket (C), and Nap (D) on the kinetics of fAß(1-40) (A, C, D) and 
fAß(1-42) (B) extension.  The reaction mixtures containing 10 µg/mL (2.3 µM) sonicated fAß(1-40) 
(A, C, D) or fAß(1-42) (B), 50 µM Aß(1-40) (A, C, D) or Aß(1-42) (B), 50 mM phosphate buffer, pH 
7.5, 100 mM NaCl, and 0 (●), 10 (○) or 50 µM (□) of Ibu (A, B), Ket (C), or Nap (D), were 
incubated at 37˚C for the indicated times.  Each point represents the mean of three 5 µL aliquots from 
the same sample.  Each figure is a representative pattern of 3 independent experiments.  (E) Effect of 
Aß(1-40) concentration on the initial rate of fAß(1-40) extension in the presence (○) and absence (●) 
of Ibu.  The reaction mixtures containing 10 µg/mL (2.3 µM) sonicated fAß(1-40), 50 mM phosphate 
buffer, pH 7.5, 100 mM NaCl, 0 (●) or 10 µM (○) Ibu, and 0, 10, 20, 30, 40, and 50 µM Aß(1-40), 
were incubated at 37˚C for 1 h.  Points represent means of three independent experiments.  In all 
points, standard errors were within symbols.  Liner least-square fit was performed for each straight line 
(R2 = 0.971 and 0.959 for ○ and ●, respectively).  




Fig. 3.   Electron micrographs of extended fAß(1-40).  The reaction mixtures containing 10 µg/mL 
(2.3 µM) fAß(1-40), 50 µM Aß(1-40), 50 mM phosphate buffer, pH 7.5, 100 mM NaCl, and 0 (B) or 
50 µM Ibu (A, C), were incubated at 37˚C for 0 (A), or 6 h (B, C).  Scale bars indicate a length of 250 
nm.   
 
Fig. 4.   Effects of Ibu (A,B), Ket (C), and Nap (D) on the kinetics of fAß(1-40) (A, C, D) and 
fAß(1-42) (B) destabilization.  The reaction mixtures containing 25 µM fAß(1-40) (A, C, D) or 
fAß(1-42) (B), 50 mM phosphate buffer, pH 7.5, 100 mM NaCl, and 0 (●), 10 (○), or 50 µM (□) of 
Ibu (A, B), Ket (C), or Nap (D), were incubated at 37˚C for the indicated times.  Each point represents 
the mean of three 5 µL aliquots from the same sample.  Each figure is a representative pattern of 3 
independent experiments.   
 
Fig. 5.   Electron micrographs of destabilized fAß(1-40).  The reaction mixtures containing 25 µM 
fAß(1-40), 50 mM phosphate buffer, pH 7.5, 100 mM NaCl, and 50 µM Ibu was incubated at 37˚C for 
0 (A), 1 (B), or 6 h (C).  Scale bars indicate a length of 250 nm.   
 
Fig. 6.   Effects of NSAIDs on the formation of fAß(1-40) (A) and fAß(1-42) (B) from fresh 
Aß(1-40) and Aß(1-42), respectively, and the destabilization of fAß(1-40) (C) and fAß(1-42) (D).  In 
(A) and (B), the reaction mixture containing 50 µM Aß(1-40) or 25 µM Aß(1-42), 50 mM phosphate 
buffer, pH 7.5, 100 mM NaCl, and 50 µM NSAIDs was incubated at 37˚C for 7 days and 24 h, 
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respectively.  In (C) and (D), the reaction mixture containing 25 µM fAß(1-40) or fAß(1-42), 50 mM 
phosphate buffer, pH 7.5, 100 mM NaCl, and 50 µM NSAIDs was incubated at 37˚C for 24 h.  Each 
column represents the average of three independent experiments.  SD is indicated by bars.  N.S. 
denotes not significant.  Significant difference (p < 0.05) was observed in all other combinations 
(one-way analysis of variance, post-hoc test by Scheffe). 
 
Fig. 7.   Dose-dependent inhibition of the formation of fAß(1-40) (A) and fAß(1-42) (B) from fresh 
Aß(1-40) and Aß(1-42), respectively, and dose-dependent destabilization of fAß(1-40) (C) and 
fAß(1-42) (D).  In (A) and (B), the reaction mixture containing 50 µM Aß(1-40) or 25 µM Aß(1-42), 
50 mM phosphate buffer, pH 7.5, 100 mM NaCl, and 0, 0.01, 0.1, 1, 10 and 50 µM NDGA (●), Rif 
(■), SSide (□), Ibu (○), or nicotine (◆) were incubated at 37˚C for 4 days or 24 h, respectively.  In 
(C) and (D), the reaction mixture containing 25 µM fAß(1-40) or fAß(1-42), 50 mM phosphate buffer, 
pH 7.5, 100 mM NaCl, and 0, 0.01, 0.1, 1, 10 and 50 µM NDGA (●), Rif (■), SSide (□), Ibu (○), or 
nicotine (◆) were incubated at 37˚C for 6 h.  Each point represents the average of three independent 
experiments.  SD is indicated by bars.  The average without compounds was regarded as 100%.  
Note that the final equilibrium levels in the presence of 50 µM SSide and Ibu were different from those 
in Fig. 6 because different lots of Aß(1-40) and Aß(1-42) (530108 and 530914, respectively) were used 
in these experiments. 
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